(Total Views: 407)
Posted On: 11/20/2023 11:23:08 AM
Post# of 148870
Sean007 wrote:
I am familiar with 2 people in the LH trial who were fortunate enough to receive LL and both experienced relief shortly after their first shot. Unfortunately, they regressed after the trial like the HIV patients you noted. One of them, Miranda Erlanson, has publicly acknowledged what LL did for her.
Here is her story from an article dated 7/5/2021. I do regret that CYDY chose not to pursue LH. It is such a large, unmet need that will continue to multiply over the years. I am hopeful that a partnership will result in resumption of work in this indication.
Erlanson enrolled in a double-blind clinical trial of a drug called leronlimab, an experimental CCR5 inhibitor designed specifically for long COVID. Erlanson did not know whether she received the drug or a placebo until the study was unblinded, at which time she received confirmation that she did receive the drug. But she says that she noticed a marked improvement in her condition about three days after she received her first dose on March 16.
“I was able to eliminate more than 24 symptoms,” Erlanson recalls. “I could think without it causing a headache. My lower body was not numb. This treatment got me out of my wheelchair, fixed the partial myoclonic jerks that I was having, and it fixed my nausea. I was able to cook, and my husband and kids were able to have a normal mom.”
CytoDyn, the company that manufactures leronlimab, said in a press release that their Phase 2 clinical trial showed a significant improvement in 18 of 24 long COVID symptoms studied in the non-placebo group. CytoDyn is working with the FDA to receive approval to proceed with a Phase 3 trial in the US. In the meantime, CytoDyn is conducting two Phase 3 trials of leronlimab in Brazil.
Erlanson has not received any doses of her trial medication since the first week of May, and since then, her symptoms have progressively returned. “I had forgotten how bad it was, and how much everything hurt. This drug is a shining light,” she says.
https://www.verywellhealth.com/long-covid-exi...ry-5189914
Quote:
"Regression by HIV patients...AFTER,.. LL was withdrawn from their medication."... Now surely... That information...would be a very positive indication of the value of the Large Molecule...in the HIV population. I see their request of a trial protocol...as a positive move towards credibility...they want us to show our hand.
I am familiar with 2 people in the LH trial who were fortunate enough to receive LL and both experienced relief shortly after their first shot. Unfortunately, they regressed after the trial like the HIV patients you noted. One of them, Miranda Erlanson, has publicly acknowledged what LL did for her.
Here is her story from an article dated 7/5/2021. I do regret that CYDY chose not to pursue LH. It is such a large, unmet need that will continue to multiply over the years. I am hopeful that a partnership will result in resumption of work in this indication.
Erlanson enrolled in a double-blind clinical trial of a drug called leronlimab, an experimental CCR5 inhibitor designed specifically for long COVID. Erlanson did not know whether she received the drug or a placebo until the study was unblinded, at which time she received confirmation that she did receive the drug. But she says that she noticed a marked improvement in her condition about three days after she received her first dose on March 16.
“I was able to eliminate more than 24 symptoms,” Erlanson recalls. “I could think without it causing a headache. My lower body was not numb. This treatment got me out of my wheelchair, fixed the partial myoclonic jerks that I was having, and it fixed my nausea. I was able to cook, and my husband and kids were able to have a normal mom.”
CytoDyn, the company that manufactures leronlimab, said in a press release that their Phase 2 clinical trial showed a significant improvement in 18 of 24 long COVID symptoms studied in the non-placebo group. CytoDyn is working with the FDA to receive approval to proceed with a Phase 3 trial in the US. In the meantime, CytoDyn is conducting two Phase 3 trials of leronlimab in Brazil.
Erlanson has not received any doses of her trial medication since the first week of May, and since then, her symptoms have progressively returned. “I had forgotten how bad it was, and how much everything hurt. This drug is a shining light,” she says.
https://www.verywellhealth.com/long-covid-exi...ry-5189914
(8)
(0)Scroll down for more posts ▼
